# Beijing Capital Science and Technology Development Group

> Beijing Capital Science and Technology Development Group is a VC fund backing Medical. See 19 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Beijing, China
- Total investments: 19
- Last investment: Jun 2026
- Lead investor: 5%
- Last updated: Aug 2026

Beijing Capital Science and Technology Development Group is a VC fund in Beijing focused on Medical and Biotechnology. BSTIG accelerates the reform of the scientific and technological system, promote the reform of public institutions

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 5 | 26% |
| Biotechnology | 3 | 16% |
| Biopharma | 2 | 11% |
| Health Care | 2 | 11% |
| Medical Device | 2 | 11% |

18 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 16% |
| Seed | 2 | 11% |
| Angel | 2 | 11% |
| Series B | 1 | 5% |
| Series E | 1 | 5% |

6 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Beijing Guomai Juneng | Beijing Guomai Juneng is a private high-tech enterprise specializing in the research and development of commercial fusion energy. |  | Angel | Jun 26, 2026 |  |
| Shuowei Optoelectronics | Shuowei Optoelectronics focuses on next-generation photovoltaic solutions for space applications. | $14.6M | Seed | Apr 30, 2026 |  |
| Baiyi Wuyou | Baiyi Wuyou is a biopharmaceutical company that specializes in the research and development of vaccines and innovative drugs. The company is dedicated to studying viral protein structural biology and antibody epitopes, with a focus on understanding the mechanisms of infectious disease infection and immune responses. |  | Series A | Jan 01, 2026 |  |
| Immunochina | ImmunoChina Pharmaceuticals manufactures medical products. The Company produces cell injections, cell therapy drugs, and other products. ImmunoChina Pharmaceuticals also provides medical technology development, medical research, medical trial development, and other services. |  | Series E | Jan 09, 2025 |  |
| Prime Gene Therapeutics | Puqi Pharmaceutical focuses on the R&D and industrialization of innovative drugs. | $41.1M | Series B | Jan 02, 2025 |  |
| FlightWin | FlightWin focuses on technology research and development, product manufacturing, and technical services of industrial-grade unmanned helicopter systems. With full R&D design, manufacturing, system integration, flight test, delivery, and after-sales service capabilities for unmanned helicopter systems, the company has a production and serviceteam. The items are frequently used in the military, military trade, emergency rescue, unmanned transportation, and other industries. |  | Series B | Dec 01, 2024 |  |
| RITS | RITS is an autonomous vehicle company that specializes in the development of advanced commercial vehicles and driverless technologies. | $13.9M | Series A | Mar 07, 2024 |  |
| Gossip Security | Gossip Security offers a code security analysis platform. They introduce a number of program analysis and artificial intelligence technologies to improve the analysis ability and accuracy of medium and high-risk security vulnerabilities, and become a developer-friendly code security analysis tool with low false positives. Their products andservices include shift left to develop security products, corax code security analysis platform, stork software composition analysis platform, security service system, penetration testing, source code audit, offensive and defensive drills, emergency response, devsecops system construction, security advisory, and safety training. |  | Seed | Jan 09, 2024 |  |
| Kunmai Medical | Beijing Kunmai Medical Technology is a medical equipment company with biological weak magnetic detection as its core technology. The company's main products are clinical class II new generation brain function imaging equipment and other biomagnetic imaging medical equipment including magnetocardiography, mainly for clinical applications inneuroscience, brain science research, neurosurgery, and psychiatric disease diagnosis. Well-known universities such as universities have established joint development and cooperative relations. |  | Venture - Series Unknown | Jan 01, 2024 |  |
| Megason Biotech | Megason Biotech is an innovative pharmaceutical supplier. | $1.9M | Angel | Jul 30, 2023 |  |

10 of 19 investments shown.

## Co-investors
- [Beijing E-town International Investment & Development](https://shizune.co/investors/profile/beiid) — VC Fund, 2 deals together
- Beijing State-owned Capital Operations and Management — VC Fund, 2 deals together
- [ZGC Group](https://shizune.co/investors/profile/zgc-group) — VC Fund, 2 deals together
- [ZGC Group](https://shizune.co/investors/profile/zhongguancun-qihang-vc) — VC Fund, 2 deals together
- [Baidu](https://shizune.co/investors/profile/baidu) — VC Fund, 1 deal together
- Beijing Commercial Aerospace and Low-altitude Economic Industry Investment Fund — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Beijing Capital Science and Technology Development Group invest in?

Beijing Capital Science and Technology Development Group invests primarily in Medical, Biotechnology and Biopharma startups, most often at Series A and Seed stage. Most of the 19 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Beijing Capital Science and Technology Development Group last invest?

The most recent investment recorded for Beijing Capital Science and Technology Development Group closed in Jun 2026. Shizune tracks 19 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co